Last reviewed · How we verify
NCT04361032: TRONCHER
Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia
Phase 3 trial testing Tocilizumab Injection in COVID19 in 260 participants. Status unknown.
4 September 2020
Quick facts
| Lead sponsor | Abderrahmane Mami Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 260 |
| Start date | 4 September 2020 |
| Primary completion | 4 September 2020 |
| Estimated completion | 4 October 2020 |
| Sites | 1 location across Tunisia |
Drugs / interventions tested
- Tocilizumab Injection — full drug profile →
- Deferoxamine (DEFEROXAMINE) — full drug profile →
Conditions studied
- COVID19 — all drugs for COVID19 →
- Intensive Care Unit — all drugs for Intensive Care Unit →
Sponsor
Abderrahmane Mami Hospital
Who can join
Adults 18 to 80, any sex, with COVID19 or Intensive Care Unit. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, associated with standards treatments in COVID-19 (+) patients, Hospitalized In Intensive care in Tunisia. Multicentric, comparative, randomized study.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts.
Wang J, Jiang M, Chen X, Montaner LJ. · · 2020 · cited 551× · PMID 32534467 · DOI 10.1002/jlb.3covr0520-272r -
COVID-19: Characteristics and Therapeutics.
Chilamakuri R, Agarwal S. · · 2021 · cited 192× · PMID 33494237 · DOI 10.3390/cells10020206 -
COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy.
Perricone C, Bartoloni E, Bursi R, Cafaro G, et al · · 2020 · cited 135× · PMID 32681497 · DOI 10.1007/s12026-020-09145-5 -
Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19 therapies (Review).
Nitulescu GM, Paunescu H, Moschos SA, Petrakis D, et al · · 2020 · cited 93× · PMID 32468014 · DOI 10.3892/ijmm.2020.4608 -
Cytokines and Chemokines in SARS-CoV-2 Infections-Therapeutic Strategies Targeting Cytokine Storm.
Pum A, Ennemoser M, Adage T, Kungl AJ. · · 2021 · cited 70× · PMID 33445810 · DOI 10.3390/biom11010091 -
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895 -
Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19.
Li X, Zhang Z, Wang Z, Gutiérrez-Castrellón P, et al · · 2022 · cited 58× · PMID 35697684 · DOI 10.1038/s41392-022-01043-6 -
Tackling the cytokine storm in COVID-19, challenges and hopes.
Abdin SM, Elgendy SM, Alyammahi SK, Alhamad DW, et al · · 2020 · cited 54× · PMID 32663575 · DOI 10.1016/j.lfs.2020.118054
Verify or expand the search:
- PubMed search for NCT04361032
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tocilizumab Injection
Trials testing the same drug.
- NCT05716035 — Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis · Phase 2, PHASE3 · unknown
- NCT04317092 — Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) · Phase 2 · unknown
- NCT05302947 — COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU · completed
- NCT03350633 — Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders · Phase 2, PHASE3 · completed
Other recruiting trials for COVID19
Currently open trials in the same condition.
- NCT07337382 — The Optimising Isolation, Quarantine and Distancing Study for COVID-19 · active not recruiting
- NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting
- NCT04367883 — Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection · recruiting
Other Abderrahmane Mami Hospital trials
Trials by the same sponsor.
- NCT06392568 — Epidemiological Features of Emergent Highly Resistant Bacteria in Tunisian Intensive Care Units · recruiting
- NCT05547646 — The Prevalence of Healthcare-associated Infection in Medical Intensive Care Units in Tunisia · completed
- NCT04528927 — Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Ac · Phase 3 · withdrawn
- NCT04351919 — Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+) · Phase 4 · withdrawn
- NCT04349228 — Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals · Phase 3 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04361032 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Abderrahmane Mami Hospital
- Last refreshed: 27 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04361032.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing